Phaseline

Companies › Shanghai YingLi Pharmaceutical

Shanghai YingLi Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YL-17231
Pan-RAS inhibitor
KRAS, HRAS, NRASPhase 1Advanced Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06096974YL-17231Phase 1Advanced Solid TumorsOncologyOct 2025

Targets

KRAS (1) HRAS (1) NRAS (1)

Companies with the same targets

Revolution Medicines Adlai Nortye Biopharma TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Guangzhou JOYO Pharma Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.